Mapping each pre-existing condition’s association to short-term and long-term COVID-19 complications

Institutional Review Board (IRB)

This retrospective research was conducted under IRB 20–003278, ‘Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions’. For further information regarding the Mayo Clinic Institutional Review Board (IRB) policy, and its institutional commitment, membership requirements, review of research, informed consent, recruitment, vulnerable population protection, biologics, and confidentiality policy, please refer to www.mayo.edu/research/institutional-review-board/overview.

Study design

In this study, we consider all hospitalized COVID-19 positive patients (positive PCR for SARS-CoV2) in the Mayo Clinic electronic health record (EHR) database from March 12, 2020 to September 15, 2020 (1,903 patients total). An overview of the clinical characteristics of this study population is provided in Table 1.

In order to capture the complications and comorbidities recorded in the clinical notes with positive sentiment, we ran the 1.1 million patient notes through a neural network based software that captures the sentiments of phenotypes from clinical notes.

For comorbidities, we considered 21 risk factors for COVID-19 severe illness reported by the CDC⁴, including: (1) anemia, (2) asthma, (3) BMI between 25-30 (overweight), (4) BMI between 30-40 (obese), (5) BMI >= 40 (severe obesity), (6) cancer, (7) cardiomyopathy, (8) chronic kidney disease (CKD), (9) chronic obstructive pulmonary disease (COPD), (10) coronary artery disease (CAD), (11) heart failure (HF), (12) hyperglycemia, (13) hypertension, (14) immunosuppressant medication usage, (15) liver disease, (16) neurologic conditions, (17) obstructive sleep apnea (OSA), (18) smoker (former or current), (19) steroid medication usage, (20) type 1 diabetes mellitus (T1D), (21) type 2 diabetes mellitus (T2D). We also note that bone marrow transplant, HIV/AIDS, pediatric conditions, pregnancy, sickle cell disease, solid organ transplant, and thalassemia were also considered, but were not included in the analysis because fewer than 20 patients had each of these comorbidities.

For complications, we considered 20 COVID-associated complications: (1) acute respiratory distress syndrome / acute lung injury (ARDS / ALI), (2) acute kidney injury (AKI), (3) anemia, (4) cardiac arrest, (5) cardiac arrhythmias, (6) chronic fatigue syndrome, (7) disseminated intravascular coagulation (DIC), (8) heart failure, (9) hyperglycemia, (10) hypertension, (11) myocardial infarction (MI), (12) pleural effusion, (13) pulmonary embolism (PE), (14) respiratory failure, (15) sepsis, (16) septic shock, (17) stroke / cerebrovascular incident, (18) venous thromboembolism / deep vein thrombosis (VTE / DVT), (19) delirium/encephelopathy, and (20) numbness.

A patient was determined to have a clinical phenotype (the comorbidity or complication, in question) if the clinical phenotype or synonyms were mentioned (with positive sentiment) within that patients’ electronic health records. For comorbidities, the mention must have occurred within a note at any point in the patient history prior to the patient’s first positive COVID-19 PCR test. Patients were only considered if they had at least one note within Mayo Clinic EHR system dated before days -31 relative to their first positive PCR test.

For the patients included in this study, we stratified the rates of new onset complications by comorbidities (Table 2). For each comorbidity, e.g. chronic kidney disease, we compare the rates of “new onset” complications in cohorts of COVID-19 patients with and without chronic kidney disease. To calculate the rate of a new-onset complication, e.g. acute kidney injury (AKI), the numerator is the number of patients with AKI recorded in the clinical notes (with positive sentiment) during but not prior to the time period. The denominator is the number of patients without AKI recorded in the clinical notes with positive sentiment prior to the time period.

Augmented curation to identify comorbidities and complications in clinical notes

An augmented curation approach was used to classify the sentiment of phenotypes mentioned in the clinical notes. In order to determine if a patient is indicative of a comorbidity or complication, we used a system consisting of:

• A high performance text retrieval and search engine that given a patient cohort consisting of one or more patients, pipes all the sentences, paragraphs and documents pertaining to those patients to a Named Entity Recognition (NER) system

• An NER system consisting of both a knowledge graph based entity recognition subsystem as well as a Bidirectional Encoder Representations from Transformers (BERT) based⁵ entity recognition system that, given any sentence or paragraph is able to identity whether it contains one or more phenotypes (comorbidities or complications etc.) so that all such sentences and paragraphs then are piped to a further downstream phenotype sentiment classification system.

• A BERT-based phenotype sentiment model³ that given a sentence or paragraph containing a phenotype/disease token provides accurately the sentiment as to whether or not the sentence indicates if the patient has the disease or not.

• A system that aggregates, patient-wise, all the sentence/paragraph sentiments, grouped by disease, and uses practical heuristics to determine if the patient may be confidently deemed to have the disease, based on the sentence level sentiments. As part of immediate future work, we are developing formal Bayesian models to aggregate the sentence level BERT sentiment information into a sound patient level sentiment inference.

• Presently we use heuristics based on the number of positive sentiment sentences found in a patient’s notes to deem whether or not the patient has a disease.

Validation of the augmented curation model

In order to validate the augmented curation model for a set of phenotypes of complications/comorbidities, we manually labelled a set of 2,404 randomly selected sentences from the clinical notes containing the phenotypes. The true positive, true negative, false positive, and false negative rates are reported in Supplementary Table S1. Overall, the out-of-sample precision, recall, and accuracy values were 0.980, 0.982, and 0.966, respectively.

Patient characteristics

1,903 patients were hospitalized with a diagnosis of COVID-19 between March 12, 2020 and October 15, 2020. Using the date of the first positive SARS-CoV-2 PCR test, we analyzed the clinical notes of each patient in their pre-COVID vs the post-COVID19 phase (Figure 1A). Using deep language models (Figure 1B) we extracted the 20 risk factors for COVID-19 severe illness reported by the CDC (Figure 1C) and the 18 COVID-associated complications (Figure 1D) in order to analyze their association in our cohort (Figure 2-4).

• Download figure
• Open in new tab

Figure 1: Study design and overview.

(A) Relative timeline for each of the patients in the study, divided into the pre-COVID phase (1 year prior to the first positive PCR test), and the SARS-CoV-2 positive phase (90 days following the first positive PCR test). (B) Clinical notes from 1903 hospitalized patients are analyzed with a Bidirectional Encoder Representations from Transformers (BERT) model to extract the presence or absence of comorbidities and complications. (C) Distribution of pre-existing conditions in the first-year before the first positive PCR test (D) Distribution of complications at early (0-31 days), and late time points (31-60 days) (61-90 days).

• Download figure
• Open in new tab

Figure 2. Heatmap showing associations between comorbidities and early-onset complications (0-30 days post-PCR) in COVID-19 patients.

The color of each (comorbidity, complication) pair corresponds to (number of patients with the comorbidity that had the complication for the first time in the time window (0-30 days)) / (Total number of patients with the comorbidity). In particular, darker shades of red correspond to higher rates of complications, and lighter shades of red correspond to lower rates of complications. A patient is determined to have a comorbidity if it is recorded in their clinical notes with positive sentiment any time before their first positive PCR test. For each comorbidity row and for each complication column, the number of patients is shown in parentheses.

In Table 1, we present the general characteristics of the study population. All age groups are included, and, as expected from the severity of the disease in different age groups, more than 50% of the patients were over 50 year-old with only 2.6% of pediatric patients. Female, male and different ethnic origins of the US population are adequately represented. The most frequent comorbidities were hypertension (42.8%), diabetes/hyperglycemia (38%), obesity (25.2%) and cancer (21.1%), reflecting the most common causes of chronic diseases in the US.

The most common COVID complications recorded were respiratory (ARDS, respiratory failure, pulmonary embolism), followed by cardiovascular (hypertension, myocardial infarction, arrhythmia, stroke), acute kidney injury, anemia, sepsis and diabetic decompensation/hyperglycemia (Figure 1D).

Frequency of COVID-19 complications and association with underlying comorbidities

The main objective of our analysis was to identify the association between comorbidities and short-term (up to 30 days post-infection) and long-term (31-90 days post-infection) complications of COVID-19 infection. Here, we observe the majority of complications occur within the first month post-infection (Figure 1D).

We identify multiple comorbidities that are associated with significantly higher rates of any complications in the early onset time period (Days 0-30 post-PCR diagnosis). From this analysis, we validate that many of the CDC-reported risk factors for COVID-19 severe illness are associated with increased rates of early onset COVID complications across multiple organ systems (Table 2). Among these we identify hypertension (RR: 9.4, p-value: 2.9e-64) as the most significant risk factor followed by other cardiovascular chronic disease (heart failure, coronary artery disease, cardiomyopathy), anemia (RR: 3.2, p-value: 9.8e-14) and chronic kidney disease (RR: 4.4, p-value: 1.5e-22), as the most significant predictors of clinical complication in early COVID-19 infection.

Respiratory complications

Pleural effusions are the most common early onset complications: 23% within the first months and 7% for ARDS/ALI, the second most frequent complication (Figure 1D). The primary risk factor for pleural effusion was hypertension (RR 9.2, p = 2.4e-22) (Figure 2, Table 3). While the risk of new onset of pleural effusion is reduced after a month, our data reveal persistent risk of pleural effusion beyond 30 days post-infection, particularly among patients with type 1 diabetes (∼5%) (Figures 3,4).

• Download figure
• Open in new tab

Figure 3. Heatmap showing associations between comorbidities and late-onset complications (31-60 days post-PCR) in COVID-19 patients.

The color of each (comorbidity, complication) pair corresponds to (Number of patients with the comorbidity that had the complication for the first time in the time window (31-60 days)) / (Total number of patients with the comorbidity). In particular, darker shades of red correspond to higher rates of complications, and lighter shades of red correspond to lower rates of complications. A patient is determined to have a comorbidity if it is recorded in their clinical notes with positive sentiment any time before their first positive PCR test. For each comorbidity row and for each complication column, the number of patients is shown in parentheses.

• Download figure
• Open in new tab

Figure 4. Heatmap showing associations between comorbidities and late-onset complications (61-90 days post-PCR) in COVID-19 patients.

The number in each (comorbidity, complication) cell corresponds to the number of patients with the comorbidity that had the complication for the first time in the time window (61-90 days). The color of each (comorbidity, complication) pair corresponds to (Number of patients with the comorbidity that had the complication for the first time in the time window (61-90 days)) / (Total number of patients with the comorbidity). In particular, darker shades of red correspond to higher rates of complications, and lighter shades of red correspond to lower rates of complications. A patient is determined to have a comorbidity if it is recorded in their clinical notes with positive sentiment any time before their first positive PCR test. For each comorbidity row and for each complication column, the number of patients is shown in parentheses.

Acute respiratory distress syndrome / acute lung injury is the second most frequent and is the most dreaded complication of severe COVID-19 infection (7%) (Figure 1D). In the early stages of COVID infection (i.e. 0-30 days post-infection), ARDS/ALI was most significantly associated with hypertension (p-value: 4.2e-8). The other most significantly associated baseline comorbidities include anemia (p-value: 2.9e-4) and chronic kidney disease (2.7e-3) (Figure 2). In later stages of infection, we observe additional instances of ARDS/ALI, but at lower rates. Further, in later stages of infection, we fail to observe significant associations between baseline comorbidities and increased risk of new onset of ARDS/ALI (Figures 3,4, Table 3).

Cardiovascular complications

Cardiac arrhythmia was the most common cardiovascular complication following COVID infection (12%) (Figure 1D). Hypertension is by far the most important risk factor (RR= 21, p = 2.7e-19) (Table 3). Up to 7% of hypertensive patients present with this complication within the first 30 days (Figure 2). But the risk declines to less than 1% for new onset after one month post-infection (Figures 3,4).

Early onset COVID heart failure is the second most common cardiovascular complication (9%) (Figure 1D). It is primarily associated with coronary heart disease (RR=7.3, p=2.9e-3) and other cardiovascular risk factors (hypertension, anemia, type 2 diabetes, smoking) (Table 3). But interestingly, cancer and immunosuppression are also uncovered as significant risk factors (RR=5.1 and 4.5, P = 4.0e-4 and 0.04, respectively). The cardiovascular complications examined in this study occur most frequently in days 0-30 post-infection (Figure 2). Beyond 30 days, the risk of new-onset arrhythmia, hypertension, MI, PE/DVT dropped to less than 1% for all comorbidities (Figures 3,4).

Renal complications

Acute kidney injury is among the most common early-onset post-COVID complications (7%), (Figure 1D) and is associated in our cohort mostly with hypertension (RR=11, p=1.2e-7), and chronic kidney disease (RR 8.9, p=4.1e-6) (Table 3) (Figure 2). Specifically, we observe acute kidney injury in 7% of hospitalized COVID patients in aggregate in early infection. The risk of acute kidney injury is highest in the early stages of infection (i.e. 0-30 days post-infection), while there is a reduction in the new onset of acute kidney injury beyond 30 days (either 31-60 days or 61-90 days) (Figures 3,4).

Neurologic Complications

Encephalopathy and delirium are a commonly observed complication of COVID (c), which is most associated in our cohort with heart failure (RR = 11, p = 3.9e-5), hypertension (RR = 7.2, p = 3.3e-4), and coronary artery disease (RR = 9.2, p = 7.5e-4) (Table 3). Further, the risk of encephalopathy and delirium was observed to be highest in early COVID infection (Figures 3,4).

Predictors of long-term complications of COVID-19 infection

While we observe a substantial reduction in the frequency of new onset of complications beyond 30 days post-infection, the risk of some complications is non-zero. In the case of pleural effusion, the risk decreases from 10-15% for all patients to less than 1% (Figures 2,3,4) with increased risk in patients with cardiomyopathy, chronic kidney disease, coronary artery disease, heart failure and hypertension. Patients with liver disease, stroke and type 1 diabetes also appear more susceptible to late-onset complications (days 31-90) (Figure 3,4).